What is Treos Bio?
Treos Bio is a clinical-stage biotechnology company dedicated to advancing cancer treatment through innovative peptide-based immunotherapies. Their proprietary platform focuses on addressing tumor and patient heterogeneity by stimulating potent cancer-specific immune responses. Unlike therapies requiring tumor biopsies, Treos Bio's approach utilizes therapeutic peptides that are effective across diverse patient populations. The company's lead candidate, PolyPEPI1018, is targeted for colorectal cancer and has demonstrated promising results in eliciting robust immunological reactions. This strategic financing is poised to accelerate the development and accessibility of their revolutionary cancer therapies.
How much funding has Treos Bio raised?
Treos Bio has raised a total of $22M across 2 funding rounds:
Private Equity
$8M
Debt
$14M
Private Equity (2017): $8M, investors not publicly disclosed
Debt (2021): $14M led by Future Fund and Luminous Ventures
Key Investors in Treos Bio
Future Fund
Future Fund is an Australian sovereign wealth fund established to invest for the benefit of future generations, focusing on meeting unfunded public sector superannuation liabilities and easing government financial pressures.
What's next for Treos Bio?
With a major strategic investment and substantial total funding, Treos Bio is positioned for significant growth and advancement in its clinical pipeline. The company's focus on off-the-shelf peptide immunotherapies suggests a strategy aimed at broad market penetration and scalability. Future developments will likely concentrate on advancing PolyPEPI1018 through clinical trials and potentially expanding its therapeutic applications to other cancer types. This capital infusion will be critical in navigating the complex regulatory pathways and scaling manufacturing capabilities to meet anticipated global demand, solidifying Treos Bio's role in the evolving landscape of cancer immunotherapy.
See full Treos Bio company page
